Federal cord blood banking program renewed with expanded inventory control
S. 4109 — Stem Cell Therapeutic and Research Reauthorization Act of 2026 · Filed by Jack Reed (D-RI) · 3 cosponsors · Introduced Mar 17, 2026 · Reported out
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill reauthorizes federal funding for stem cell research and cord blood banking programs under the C.W. Bill Young Cell Transplantation Program, increasing appropriations to $33 million annually through 2031. It updates the National Cord Blood Inventory management framework, allowing the Secretary of Health and Human Services to transfer units between banks, retire low-quality units, and manage inventory based on scientific evidence and clinical utility.
Why we flagged it
The bill extends federal funding and updates operational standards for a public cord blood banking program serving transplant patients. It is a routine reauthorization with modernized inventory management provisions.
What the text implies
- The Secretary gains broad discretion to retire or transfer cord blood units based on 'scientific and clinical evidence' without explicit statutory criteria, potentially reducing inventory availability if interpreted narrowly.
- The bill does not specify what happens to transferred units or establish appeal rights for cord blood banks whose units are deemed non-compliant, creating potential for operational disruption.
The full analysis lists 3 implications of this text.
Who stands to gain
cord blood banks (public and nonprofit entities receiving federal contracts); transplant centers and hospitals (indirect beneficiaries through inventory access)